{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:09:27Z","timestamp":1790392167416,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.cbi.2021.109480","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T08:56:21Z","timestamp":1618908981000},"page":"109480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles"],"prefix":"10.1016","volume":"343","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-114X","authenticated-orcid":false,"given":"Amgad M.","family":"Rabie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2021.109480_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health \u2013 The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cbi.2021.109480_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.micinf.2020.02.002","article-title":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future","volume":"22","author":"Li","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.cbi.2021.109480_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/22221751.2020.1723441","article-title":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies","volume":"9","author":"Jiang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.cbi.2021.109480_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1039\/D0NJ03708G","article-title":"Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): Successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs","volume":"45","author":"Rabie","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.cbi.2021.109480_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s11696-021-01640-9","article-title":"Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug","author":"Rabie","year":"2021","journal-title":"Chem. Pap."},{"key":"10.1016\/j.cbi.2021.109480_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cbi.2021.109480_bib8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing: Old drugs learn new tricks","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med."},{"issue":"273","key":"10.1016\/j.cbi.2021.109480_bib9","article-title":"Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cbi.2021.109480_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discoveries Ther."},{"key":"10.1016\/j.cbi.2021.109480_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.cbi.2021.109480_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cbi.2021.109480_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.cbi.2021.109480_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.cbi.2021.109480_bib15","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cbi.2021.109480_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.cbi.2021.109480_bib17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: An open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.cbi.2021.109480_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019\u2010nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2021.109480_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2021.109480_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109815","article-title":"Does zinc supplementation enhance the clinical efficacy of chloroquine\/hydroxychloroquine to win today's battle against COVID-19?","volume":"142","author":"Derwand","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"16","key":"10.1016\/j.cbi.2021.109480_bib21","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discovery"},{"issue":"28","key":"10.1016\/j.cbi.2021.109480_bib22","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discovery"},{"key":"10.1016\/j.cbi.2021.109480_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5923\/j.ajoc.20160602.02","article-title":"Design, synthesis, and biological evaluation of novel 5-substituted-2-(3,4,5-trihydroxyphenyl)-1,3,4-oxadiazoles as potent antioxidants","volume":"6","author":"Rabie","year":"2016","journal-title":"Am. J. Org. Chem."},{"key":"10.1016\/j.cbi.2021.109480_bib24","first-page":"21","article-title":"Design, synthesis, and biological evaluation of new 5-substituted-1,3,4-thiadiazole-2-thiols as potent antioxidants","volume":"10","author":"Rabie","year":"2018","journal-title":"Researcher"},{"key":"10.1016\/j.cbi.2021.109480_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cofs.2020.08.004","article-title":"Potential use of polyphenols in the battle against COVID-19","volume":"32","author":"Paraiso","year":"2020","journal-title":"Curr. Opin. Food Sci."},{"key":"10.1016\/j.cbi.2021.109480_bib26","doi-asserted-by":"crossref","first-page":"109211","DOI":"10.1016\/j.cbi.2020.109211","article-title":"Roles of flavonoids against coronavirus infection","volume":"328","author":"Russo","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2021.109480_bib27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.sjbs.2020.10.028","article-title":"Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study","volume":"28","author":"Rameshkumar","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.cbi.2021.109480_bib28","doi-asserted-by":"crossref","first-page":"107351","DOI":"10.1016\/j.compbiolchem.2020.107351","article-title":"Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design","volume":"88","author":"Meyer-Almes","year":"2020","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.cbi.2021.109480_bib29","doi-asserted-by":"crossref","first-page":"153311","DOI":"10.1016\/j.phymed.2020.153311","article-title":"Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic","volume":"85","author":"Khalifa","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cbi.2021.109480_bib30","doi-asserted-by":"crossref","first-page":"112653","DOI":"10.1016\/j.ejmech.2020.112653","article-title":"Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses","volume":"203","author":"Nebigil","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2021.109480_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.aimed.2020.07.007","article-title":"The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review","volume":"7","author":"Aucoin","year":"2020","journal-title":"Adv. Integr. Med."},{"key":"10.1016\/j.cbi.2021.109480_bib32","article-title":"van Hemert, Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture","volume":"6","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cbi.2021.109480_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.cbi.2021.109480_bib34","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.cbi.2021.109480_bib35","series-title":"COVID-19 Docking Server (Homepage on the Internet), Shan Chang Lab., Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering","year":"2020"},{"key":"10.1016\/j.cbi.2021.109480_bib36","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"Web Server issue","key":"10.1016\/j.cbi.2021.109480_bib38","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gki481","article-title":"PatchDock and SymmDock: servers for rigid and symmetric docking","volume":"33","author":"Schneidman-Duhovny","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cbi.2021.109480_bib41","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gkv315","article-title":"PLIP: fully automated protein-ligand interaction profiler","volume":"43","author":"Salentin","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cbi.2021.109480_bib42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/clinchem\/hvaa029","article-title":"Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia","author":"Chu","year":"2020","journal-title":"Clin. Chem. 66"},{"key":"10.1016\/j.cbi.2021.109480_bib43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.cbi.2021.109480_bib44","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2021.109480_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8101610","article-title":"Detailed molecular interactions of favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus polymerases in silico","volume":"8","author":"Sada","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.cbi.2021.109480_bib46","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.3390\/molecules25235695","article-title":"Targeting the RdRp of emerging RNA viruses: The structure-based drug design challenge","volume":"25","author":"Picarazzi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.cbi.2021.109480_bib47","article-title":"Covid-19: New coronavirus variant is identified in UK","volume":"371","author":"Wise","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cbi.2021.109480_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2021.109480_bib49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","article-title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies","volume":"17","author":"Yi","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cbi.2021.109480_bib50","article-title":"\"Expert reaction to South African variant of SARS-CoV-2, as mentioned by Matt Hancock at the Downing Street press briefing\"","volume":"23","year":"2020","journal-title":"Science Media Centre, 23 December 2020"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721001162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721001162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:03:39Z","timestamp":1757858619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279721001162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":46,"alternative-id":["S0009279721001162"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109480","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109480"}}